Lexipafant is primarily used in medical research and therapeutic applications due to its role as a platelet-activating factor (PAF) antagonist. It has been studied for its potential to treat conditions associated with inflammation and immune responses, such as acute pancreatitis and sepsis. By inhibiting PAF, Lexipafant helps reduce inflammatory processes, making it a candidate for managing severe inflammatory disorders. Additionally, it has been explored in clinical trials for its efficacy in improving outcomes in critically ill patients by modulating the body's inflammatory pathways. Its application extends to experimental models where controlling PAF-mediated responses is crucial for understanding disease mechanisms and developing targeted therapies.